Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.

2.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group.

Neurology. 2018 Dec 11;91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16.

3.

Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.

McBurnett K, Clemow D, Williams D, Villodas M, Wietecha L, Barkley R.

J Child Adolesc Psychopharmacol. 2017 Feb;27(1):38-42. doi: 10.1089/cap.2016.0115. Epub 2016 Nov 15.

PMID:
27845858
4.

Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.

Shaywitz S, Shaywitz B, Wietecha L, Wigal S, McBurnett K, Williams D, Kronenberger WG, Hooper SR.

J Child Adolesc Psychopharmacol. 2017 Feb;27(1):19-28. doi: 10.1089/cap.2015.0189. Epub 2016 Jul 13.

5.

Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.

Wietecha LA, Clemow DB, Buchanan AS, Young JL, Sarkis EH, Findling RL.

CNS Neurosci Ther. 2016 Jul;22(7):546-57. doi: 10.1111/cns.12533. Epub 2016 Feb 28.

6.

Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.

Wietecha LA, Wang S, Saylor KE, Day KA, Wu SH, Kelsey D.

Clin Pediatr (Phila). 2015 Feb;54(2):164-73. doi: 10.1177/0009922814555973. Epub 2014 Nov 4.

PMID:
25371450
7.

Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.

Shaywitz BA, Williams DW, Fox BK, Wietecha LA.

J Child Adolesc Psychopharmacol. 2014 Oct;24(8):419-25. doi: 10.1089/cap.2013.0148. Epub 2014 Oct 9.

PMID:
25299355
8.

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.

Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK.

J Child Adolesc Psychopharmacol. 2014 Oct;24(8):426-34. doi: 10.1089/cap.2014.0005. Epub 2014 Jul 14.

9.

Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies.

Wietecha LA, Ruff DD, Allen AJ, Greenhill LL, Newcorn JH.

J Clin Psychiatry. 2013 Mar 29;74(12):1217-23. doi: 10.4088/JCP.12m07991.

PMID:
24434090
10.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

11.

Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning.

Wietecha L, Young J, Ruff D, Dunn D, Findling RL, Saylor K.

Clin Neuropharmacol. 2012 May-Jun;35(3):125-33. doi: 10.1097/WNF.0b013e3182560315.

PMID:
22561876
12.

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.

Young JL, Sarkis E, Qiao M, Wietecha L.

Clin Neuropharmacol. 2011 Mar-Apr;34(2):51-60. doi: 10.1097/WNF.0b013e31820c00eb.

PMID:
21406998
13.

Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States.

Meyers J, Classi P, Wietecha L, Candrilli S.

Child Adolesc Psychiatry Ment Health. 2010 Dec 14;4:31. doi: 10.1186/1753-2000-4-31.

14.

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.

Saylor K, Williams DW, Schuh KJ, Wietecha L, Greenbaum M.

Curr Med Res Opin. 2010 Sep;26(9):2087-95. doi: 10.1185/03007995.2010.493747.

PMID:
20642391
15.

Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

Wietecha LA, Williams DW, Herbert M, Melmed RD, Greenbaum M, Schuh K.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):719-30. doi: 10.1089/cap.2008.074.

PMID:
20035590
16.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia.

Sumner CR, Gathercole S, Greenbaum M, Rubin R, Williams D, Hollandbeck M, Wietecha L.

Child Adolesc Psychiatry Ment Health. 2009 Dec 15;3:40. doi: 10.1186/1753-2000-3-40.

Supplemental Content

Loading ...
Support Center